Form 4 KALOBIOS PHARMACEUTICALS For: Nov 16 Filed by: Shkreli Martin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Shock of Epic Short Squeeze in KaloBios Pharma (KBIO) Reverberates Across Wall Street
November 19, 2015 1:36 PM ESTThe stock being talked about the most on trading desks today is KaloBios Pharma (NASDAQ: KBIO). After closing at around $2 per share, shares surged to as high as $21.05 (+953%) following a disclosure after the close from Turing Pharmaceuticals' Martin Shkreli, a man demonized for jacking up drug prices, that he accumulated 1.2 million shares.
$2... $4... $6... $10... $12... shares keep climbing as short sellers were left stunned.
You see, just... More
Anthion Partners II Buys ~700K Shares of KaloBios Pharma (KBIO), Adding to Madness
November 18, 2015 5:39 PM ESTIn addition to the Martin Shkreli buys on KaloBios Pharma (NASDAQ: KBIO) disclosed after the close, Anthion Partners II disclosed it bought 713,726 shares on 11/16 at $1.26-$1.76. Shares are up 700% after-hours.
... MoreWith Shkreli Spike, KaloBios Pharma (KBIO) May Be Overvalued by a Factor of 4
November 18, 2015 4:57 PM ESTThe upside being seen in KaloBios Pharma (NASDAQ: KBIO) after the close (400%+) after Martin Shkreli... More
KaloBios Pharma (KBIO) Pops on Shkreli Insider Buy
November 18, 2015 4:25 PM ESTKaloBios Pharma (NASDAQ: KBIO) ripping higher as Martin Shkreli purchased shares.
Shkreli disclosed buying 1,211,115 shares from November 16, 2015-November 17, 2015. Prices paid ranged from $0.61-$2.43.
On November 13, 2015, KaloBios announced that it will wind down its operations and that it has engaged the Brenner... More
